Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
NCT03394885Phase 2Completed
- Sponsor
- Duke University
- Start
- Jun 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in ovarian cancer, sponsored by Duke University. Primary endpoints: Incidence of Post Chemotherapy Surgical Debulking at 9 weeks, Incidence of Treatment Emergent Adverse Events at 18 months and 2 more. Started Jun 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03394885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394885.